Business
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...
About this update from Nanoviricides, Inc.
[{"type":"text","content":"SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that it is forging ahead with advancing its lead candidate NV-387 into Phase II clinical drug development.","length":423,"tagName":"p"},{"type":"text","content":"NanoViricides has chosen MPox as the first indication to advance NV-387 into Phase II clinical trials out of the four indications for which the Company has substantial efficacy data in animal studies, namely RSV, Influenza, COVID, and Orthopoxviruses (MPox/Smallpox).","length":267,"tagName":"p"},{"type":"text","content":"The MPox program enables advancing its pipeline towards revenue in the fastest possible manner, the Company believes. The Company intends to advance NV-387 against respiratory infections soon after the Phase II clinical trial of NV-387 for the treatment of MPox infection gets under way.","length":287,"tagName":"p"},{"type":"text","content":"NanoViricides has already added one Clinical trial Site to the MPox Phase II Program.","length":85,"tagName":"p"},{"type":"text","content":"A Phase II Clinical Trial Protocol has been developed with the Principal Investigator at this site in the Democratic Republic of Congo (DRC), and this Protocol is undergoing final refinements.","length":192,"tagName":"p"},{"type":"text","content":"A Clinical Trial Application is in development with many parts having been substantially completed.","length":99,"tagName":"p"},{"type":"text","content":"NanoViricides has engaged a Clinical Research Organization (CRO) to organize and conduct this Phase II clinical trial for the treatment of MPox with NV-387, as previously stated, and this CRO has organized the Clinical Trial Site and is preparing the CTA with the Company's inputs.","length":285,"tagName":"p"},{"type":"text","content":"The manufacture of the drug substance NV-387 is substantially completed at the Company's own facility. The manufacture of the drug product "NV-387 Oral Gummies" is in progress.","length":190,"tagName":"p"},{"type":"text","content":"MPox as the first indication has several strategic benefits for the Company.","length":76,"tagNa...